DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
PECATI
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients
THYMIC
(Journal) Clinical Lung Cancer
2021
METALLICA
Metaformin in the prevention of hyperglycemia in patients with PIK#CA-mutated, hormone receptor (HR)[+]/HER2[-] advanced breast cancer treated with alpelisib plus fulvestrant: METALLICA study
BREAST
ESMO Breast
2021
OTHER
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
BREAST
(Journal) npj Breast Cancer
2021
OTHER
Nobody dares stopping clinical research, not even COVID-19
COVID-19
(Journal) npj Breast Cancer
2021
OTHER
CDK4/6 inhibitors in breast cancer: spotting the difference
BREAST
(Journal) Cancer Therapy
2021
OTHER
The impact of excluding nonrandomized studies from systemic reviews in rare diseases: "The example of meta-analyses evaluating the efficacy and safety of enzyme replacement therapy in patients with mucopolysaccharidosis"
RARE DISEASES
(Journal) Frontiers in Molecular Biosciences
2021
OTHER
PI3K activation promotes resistance to eribulinin HER2-negative breast cancer
BREAST
(Journal) British Journal of Cancer
2021
PHERGAIN
Chemotherapy de-escalation using an ¹⁸F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
BREAST
(Journal) The Lancet
2021
RESPONSE
Predictors of 18F-fluorodexoxyglucose positron-emssion tomography-driven disease detection in pateins with HER2[+] early breast cancer. A substudy of the PHERGAIN trial
BREAST
ESMO Breast
2020
EXCAAPE
223Ra in asymptomatic patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide: EXCAAPE study
PROSTATE
ESMO
2020
LUPER
Lurbinectedin in combination with Pembrolizumab forpatients with relapsed Small Cell Lung Cancer.LUPER Clinical Trial.
LUNG
IASLC
2020
TRANSFAL
TransFAL: Establishment of clinical trial-matched Patient-Derived Xenografts (PDX) for translational studies
BREAST
ESMO
2020
Other MEDSIR related articles
